Literature DB >> 10147286

Third generation cephalosporins in the parenteral to oral switch.

D Rimmer1.   

Abstract

In the present economic climate, it is increasingly necessary to ensure the cost-effectiveness of all aspects of healthcare. The expenditure on medications in a hospital is largely determined by the workload and throughput, but efforts to rationalise the use of medications will result in benefits both in patient care and overall costs. The purpose of this report is to discuss the advantages of switching from parenteral to oral cephalosporin therapy after the initial stage of infection treatment, the potential of presently available oral cephalosporins for use in a parenteral-to-oral switch regimen, and the outcome of a parenteral-to-oral switch programme, which used parenteral cefotaxime and oral cefixime, implemented at Hillingdon Hospital.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 10147286     DOI: 10.2165/00019053-199400052-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

1.  Efficacy and tolerability of cefixime in otitis media. A multicentre study in over 25,000 children.

Authors:  D H Wu
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  Bacteremia in the 1980s with special reference to the role of cefotaxime.

Authors:  H C Neu
Journal:  Clin Ther       Date:  1981       Impact factor: 3.393

3.  Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro and in vivo).

Authors:  E Schrinner; M Limbert; L Penasse; A Lutz
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  Cefotaxime in the treatment of pneumococcal pneumonia.

Authors:  S G Jenkinson; M S Briggs; R D Bryn
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.

Authors:  R Wise; S Baker; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.

Authors:  J W Stone; G Linong; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-02       Impact factor: 5.790

7.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

8.  In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.

Authors:  H C Neu
Journal:  Pediatr Infect Dis J       Date:  1987-10       Impact factor: 2.129

9.  Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.

Authors:  E L Francke; H C Neu
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

10.  Economic impact of streamlining antibiotic administration.

Authors:  R Quintiliani; B W Cooper; L L Briceland; C H Nightingale
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

View more
  4 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 2.  Management of reflux disease.

Authors:  J Dent
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 4.  Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

Authors:  A Markham; R N Brogden
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.